Market closedNon-fractional
Natera/NTRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
NTRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Austin, United States
Employees
3,288
Website
www.natera.com
Natera Metrics
BasicAdvanced
$13B
Market cap
-
P/E ratio
-$3.12
EPS
1.38
Beta
-
Dividend rate
Price and volume
Market cap
$13B
Beta
1.38
Financial strength
Current ratio
4.123
Quick ratio
3.83
Long term debt to equity
43.751
Total debt to equity
55.382
Interest coverage (TTM)
-30.10%
Management effectiveness
Return on assets (TTM)
-17.14%
Return on equity (TTM)
-50.59%
Valuation
Price to revenue (TTM)
9.911
Price to book
15.7
Price to tangible book (TTM)
15.7
Price to free cash flow (TTM)
-60.656
Growth
Revenue change (TTM)
39.26%
Earnings per share change (TTM)
-41.53%
3-year revenue growth (CAGR)
39.07%
3-year earnings per share growth (CAGR)
0.06%
What the Analysts think about Natera
Analyst Ratings
Majority rating from 17 analysts.
Natera Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$368M
18.19%
Net income
-$68M
-13.46%
Profit margin
-18.35%
-26.80%
Natera Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.97
-$0.95
-$0.64
-$0.56
-
Expected
-$1.09
-$0.96
-$0.73
-$0.71
-$0.69
Surprise
-11.35%
-0.60%
-12.03%
-20.60%
-
Natera News
AllArticlesVideos
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
Business Wire·3 weeks ago
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
Business Wire·1 month ago
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $13B as of July 27, 2024.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of July 27, 2024.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Natera stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.